Dr. Douglas Weckstein, MD
Claim this profileSolinsky Center for Cancer Care
Expert in Cancer
Expert in Lung Cancer
51 reported clinical trials
126 drugs studied
About Douglas Weckstein, MD
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Serves as Principal Investigator for the PREDICT-RT Trial at Solinsky Center for Cancer Care.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Douglas Weckstein, MD is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Ribociclib vs. Palbociclib
for Breast Cancer
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.
Recruiting4 awards Phase 311 criteria
More about Douglas Weckstein, MD
Clinical Trial Related5 years of experience running clinical trials · Led 51 trials as a Principal Investigator · 28 Active Clinical TrialsTreatments Douglas Weckstein, MD has experience with
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Nivolumab
- Atezolizumab
- Radiation Therapy
Breakdown of trials Douglas Weckstein, MD has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Douglas Weckstein, MD specialize in?
Douglas Weckstein, MD focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Douglas Weckstein, MD currently recruiting for clinical trials?
Yes, Douglas Weckstein, MD is currently recruiting for 27 clinical trials in Manchester New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Douglas Weckstein, MD has studied deeply?
Yes, Douglas Weckstein, MD has studied treatments such as Pembrolizumab, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with Douglas Weckstein, MD?
Apply for one of the trials that Douglas Weckstein, MD is conducting.
What is the office address of Douglas Weckstein, MD?
The office of Douglas Weckstein, MD is located at: Solinsky Center for Cancer Care, Manchester, New Hampshire 03103 United States. This is the address for their practice at the Solinsky Center for Cancer Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.